Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group;Effetti della somministrazione di buprenorfina transdermica in pazienti oncologici. Risultati di uno studio di outcome

Recenti Progressi in Medicina

Volumn 99, Issue 11, 2008, Pages 538-551

  Greco, Maria Teresa ^a   Deandrea, Silvia ^a   Corli, Oscar ^a   Montanari, Mauro ^a   Caraceni, Augusto ^b   Apolone, Giovanni ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Buprenorphine; Cancer pain; Opioids; Transdermal formulation

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CORTICOSTEROID; OPIATE;

ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PATIENT; COLORECTAL CANCER; GYNECOLOGIC CANCER; HUMAN; ITALY; MAJOR CLINICAL STUDY; METASTASIS; PANCREAS CANCER; PROSTATE CANCER; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMACH CANCER; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 57649178617     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-49.
2. World Health Organization. Cancer pain relief, 2nd ed. Geneva: World Health Organization 1996.
3. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. Clinical Practice Guideline No. 9 AHCPR Pub. No. 94-0592. Rockville: Agency for Health Care and Research, US Department of Health and Human Services, Public Health Service, 1994.
4. Hanks GW, De Conno F, et al, members of the Steering Committee of the Research network of the European Association for Palliative Care: Expert Working Group. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84: 587-93.
5. Cohen MZ, Easley MK, Ellis C, et al. for the JCA-HO. Cancer pain management and the JCAHO's Pain Standards. An institutional challenge. J Pain Symptom Manage 2003; 25: 519-27.
6. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; Jul 15.
7. Maltoni M. Opioids, pain, and fear. Ann Oncol 2008; 19: 5-7.
8. Ripamonti C, De Conno F, Blumbhuber H, et al. Morphine for relief of cancer pain. Lancet 1996; 347: 1262-3.
9. Quigley C. The role of opioids in cancer pain. BMJ 2005; 331: 825-829.
10. Reid CM., Gooberman-Hill R, Hanks GW. Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Annal Oncol 2008; 19: 44-8.
11. L'uso dei farmaci in Italia. Rapporto nazionale gennaio-settembre 2007. Osservatorio Nazionale sull'impiego dei farmaci http://www.agenziafarmaco.it/ allegati/osmed_gs2007.pdf
12. Apolone G, Mosconi P, Colombo P, Tamburini M. Il dolore nel paziente con cancro: un progetto di ricerca. Ricerca & Pratica 2004; 20: 137-43.
13. Apolone G, Mangano S, Compagnoni A, Negri E, et al. A Multidisciplinary project to improve the quality of cancer pain management in Italy. Background, methods, and preliminary results. J Ambul Care Manage 2006; 29: 332-41.
14. Apolone G, Bertetto O, Caraceni A, Corli O, et al. Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health Qol Life Outcomes 2006; 4: 88.
15. Apolone G, Corli O, Greco MT, Zagonel V; CPOR SG Investigators. Factors influencing the decision to take or reject opioids for cancer pain: are we on target? Ann Oncol 2008; 19: 1021-2. Epub 2008 March 28.
16. Clivio L, Tinazzi A, Mangano S, Santoro E The contribution of information technology: towards a better clinical data management Drug Dev Res 2006; 67: 245-50.
17. Caraceni, A., Mendoza, T., Mencaglia, E., Baratella, Edwards K, Forjaz MJ, et al. A validation study of the Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 1996; 65: 87-92.
18. Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain. A RCT. JAMA 2004; 291: 1333-41.
19. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, et al The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006, 42: 55-64.
20. Sweeney C, Bruera ED. Opioids side effects and management. In: Cancer pain, assessment and management. Edited by Bruera ED, Portenoy RK. Cambridge: Cambridge University Press 2003.
21. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27: 5178-89.
22. Sittl R, Likar P, Poulsen-Nautrup B. Equipotent doses of transdermal buprenorphine in patients with cancer and non-cancer pain:results from a retrospective cohort study. Clin Ther 2005; 27: 225-37.
23. Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT, on behalf of the Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group (CPOR SG). Proposto per la pubblicazione.
24. Apolone G, Corli O, Negri E, Mangano S, Montanari M, Greco MT, on behalf of the Writing Protocol Committee and the Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Effects of transdermal buprenorphine on analgesic and palliative outcomes in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group.
25. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double blind, placebo controlled trial. Clin Ther 2003; 25: 150-68.
26. Bohme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic 2003; 15: 19.
27. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Results from a phase III, multicenter, randomized, double-blind, placebo controlled study. Clin Therapeutics 2004; 26: 1808-20.
28. Giardina V, Invernizzi A, Baiardi P, Radelli S, Miotti D. Studio pilota randomizzato per il controllo del dolore di origine neoplastica tramite somministrazione di fentanyl o buprenorfina per via transdermica. Rivista Italiana di Cure Palliative 2005; 3: 30-35
29. Pace Mc, Passavanti MB, Grella E, Mazzariello L, et al. Buprenorphine in long term control of chronic pain in cancer patients. Frontiers in Bioscience 2007;1: 1291-99.
30. Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Casuccio A. safety and effectiveness of intravenous morphine for episodic breaktrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 2006; 32: 175-9.
31. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13179 patients. Curr Med Res Opin 2005; 21: 1147-58.
32. Murriel C, Falde I, Micò J, Neira M, Sanchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational study. Clin Therapeutics 2005; 27: 451-62-
33. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94:149-58.
34. Caraceni A, Cherny N, Faisenger R, Kaasa S, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an experts working group of the European Association of Palliative Care. J Pain Symptom Manage 2002; 23: 239-55.
35. Holen JC, Polit C, Hjermstad MJ, Hoge JH, Fayers PM, Caraceni A, et al. Pain assessment tools: is the content appropriate for the use in palliative care? J Pain Symptom Manage 2006; 32: 567-80.
36. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63.
37. Sturmer T, Schneeweiss S, Avorn J, Glynn RJ. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 2005; 162: 279-89.
38. Cavuto S, Bravi F, Grassi MC, Apolone G. Propensity score for the analysis of observational data: an introduction and an illustrative example Drug Develo Res 2006; 67: 208-16.